Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

“we have completed the enrollment of over 2,000 cases in December 2023. For the primary endpoint, the time to resolution of all COVID-19-related symptoms, all 15 symptoms, was determined after consultation with the FDA. In addition, we have obtained data on the suppression of the incidence of Long COVID, so-called sequelae, at 12 weeks, and we are verifying this as well in SCORPIO-HR trial. We are keeping the data up to three months under blind, so we expect to be able to present our results to you in April on these results as a topline after a three-month follow-up starting in December.”

April came and went with no PR. You would think an outright hit or miss would be a straightforward readout so perhaps they are doing some post hoc data mining? Could also be they decided to keep the trial blinded out to 24 weeks who knows

dewophile, thanks for the link and the comments. My take is that they missed the primary end point and are on the edge of the long-Covid data so are extending the trial to see if they can at least hit the reduction in the incidence of long Covid.

I think as you and DewDiligence posted, that the $3 billion number for Paxlovid sales is providing a boost to ENTA so that EDP-235 may have some value after all.